Please assess the completion status of the following clinical trial:

Trial Title: AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Acute myeloid leukemia diagnosed by WHO criteria with one of the following:~   1. Primary refractory disease following \>= 1 rounds of induction chemotherapy~  2. First relapse or higher~2. Age between 18 and 70 years of age~3. Adequate organ function defined as Creatinine \<= 1.5 x institutional ULN; AST, ALT, total bilirubin \<= 2 x ULN; Left ventricular ejection fraction of \>= 40% by MUGA scan~4. Women of childbearing potential and sexually active males must be willing and able to use effective contraception while on study~5. Able to provide signed informed consent prior to registration on study~Exclusion Criteria:~1. Acute promyelocytic leukemia (AML with t(15;17)(q22;q11) and variants)~2. Peripheral blood blast count \> 20 x 103 /mm3~3. Active CNS involvement with leukemia~4. Previous treatment with MEC or other regimen containing both mitoxantrone and etoposide~5. Pregnant or nursing~6. Receiving any other investigational agent~7. Colony stimulating factors filgrastim, pegfilgrastim or sargramostim within 2 weeks of study~8. Less than 2 weeks from the completion of any previous cytotoxic chemotherapy~9. Severe concurrent illness that would limit compliance with study requirements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Phase I Dose Escalation (Type: EXPERIMENTAL): * AMD3100 SQ on days 0-5~* Mitoxantrone on days 1-5~* Etoposide on days 1-5~* Cytarabine on days 1-5~Dose Level 1 AMD3100 dose = 80 mcg/kg/d~Dose Level 2 AMD3100 dose = 160 mcg/kg/d
- Phase II Dose Treatment (Type: EXPERIMENTAL): * AMD 3100 SQ on days 0-5~* Mitoxantrone on days 1-5~* Etoposide on days 1-5~* Cytarabine on days 1-5~Dose Level 3 AMD3100 dose=240 mcg/kg/d (this was the Phase II dose)

Based on this trial design, predict the completion outcome and termination type (if applicable).